A 72-year-old man presents to the clinic to discuss adding a newly approved medication, my… — USMLE Step 3

A 72-year-old man presents to the clinic to discuss adding a newly approved medication, myotropib, for his heart failure with preserved ejection fraction (HFpEF). He currently takes a loop diuretic, an angiotensin II receptor blocker, and a beta-blocker. His medical history is also notable for severe chronic obstructive pulmonary disease (COPD) requiring continuous home oxygen therapy.

The physician reviews a promotional brochure provided by the manufacturer. The brochure highlights the primary results of a large, randomized, double-blind, placebo-controlled trial, demonstrating that myotropib reduces the composite endpoint of heart failure hospitalization and cardiovascular death by a relative risk of 30% (Hazard Ratio [HR] 0.70, 95% Confidence Interval [CI] 0.62–0.79, $p < 0.001$ ).

The physician then examines the supplementary appendix of the trial, which includes the following subgroup analysis data for the primary endpoint:

Subgroup	Number of Patients	HR (95% CI)
Overall Cohort	8,400	0.70 (0.62–0.79)
Age	$0.45$
$< 65$ years	3,200	0.68 (0.55–0.84)
$\geq 65$ years	5,200	0.71 (0.61–0.83)
COPD Status	$0.002$
No COPD	6,100	0.55 (0.48–0.63)
COPD	2,300	0.99 (0.85–1.15)

Based on the provided literature excerpt and the patient's history, which of the following is the most accurate interpretation of the data and the most appropriate clinical decision?

COPD status acts as an effect modifier; do not initiate the medication as the patient is unlikely to derive cardiovascular benefit.Answer
B
COPD status is a confounding variable; initiate the medication because randomization adequately controls for baseline differences.
C
The interaction analysis utilized an inappropriate statistical test for time-to-event data; initiate the medication based on the overall trial efficacy.
D
The hazard ratio for patients with COPD indicates a toxic pharmacodynamic interaction; do not initiate the medication as it is absolutely contraindicated.
E
The trial data requires isolated laboratory confirmation of baseline inflammatory markers before application; order a C-reactive protein level before deciding.

Answer

COPD status acts as an effect modifier; do not initiate the medication as the patient is unlikely to derive cardiovascular benefit.

The correct answer accurately identifies that COPD status is an effect modifier. This is evidenced by the differing hazard ratios between the strata (0.55 vs. 0.99) and the statistically significant interaction term (

p = 0.002

). Because the patient has COPD, the physician must look at the specific HR for that subgroup (0.99, 95% CI 0.85-1.15). Since the confidence interval crosses 1.0, the drug provides no statistically significant cardiovascular benefit for patients with COPD, making it inappropriate to initiate.

Step-by-Step Solution

Analyze the subgroup data for Age and COPD status, focusing on the hazard ratios (HR), confidence intervals (CI), and interaction p-values.

The Age subgroup shows no significant interaction (

p = 0.45

) and similar HRs across strata. The COPD subgroup shows a highly significant interaction (

p = 0.002

) with markedly different HRs between those with COPD (HR 0.99) and without COPD (HR 0.55).

Interaction p-values determine if a third variable significantly alters the treatment effect across different strata.

Identify the statistical phenomenon occurring in the COPD subgroup.

The differing magnitude of effect between strata combined with a statistically significant interaction term defines effect modification.

Effect modification occurs when the true effect of an exposure on an outcome varies depending on the level of a third variable. It is a biological phenomenon to be reported, unlike confounding, which is a distortion to be controlled.

Apply the subgroup findings to the specific patient in the vignette.

The patient has severe COPD. In the trial, patients with COPD had an HR of 0.99 with a 95% CI of 0.85–1.15.

To practice evidence-based medicine, trial data must be applied directly to the patient's characteristics when valid subgroup data exists.

Interpret the clinical meaning of the HR for the patient's subgroup and formulate a management plan.

Because the 95% CI for the COPD subgroup crosses 1.0, there is no statistically significant difference in outcomes between the drug and placebo. The medication should not be prescribed as it offers no benefit.

A hazard ratio whose confidence interval includes 1.0 indicates a lack of statistical significance, meaning the null hypothesis (no difference between groups) cannot be rejected.

Key Concept

Effect modification is present when the effect of an exposure on an outcome differs across strata of a third variable, indicated by a significant interaction p-value. In clinical literature, this guides personalized medical decisions based on patient characteristics.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic